medical oncologist, breast cancer immunotherapy investigator, mother, PI and associate prof at NKI, happy in Amsterdam
Amsterdam
Joined June 2020
- Tweets680
- Following458
- Followers1.9K
- Likes2.2K
Excited to present 🎤 first data #SABCS24 from TONIC2. Follow-up from nature.com/articles/s41591-0…. Are immune induction with dox or cisplatin indeed benefiting pts? @VeerleGeurts at P1-7-30 and new data on acquired resist🔬 to aPD1 at PS17-09 @NKI_nl @OncoAlert @NatureMedicine
Recent Nature paper on phase of menstrual cycle at start of breast cancer chemo suggests that this can affect chemo-sensitivity. More research needed on how this can result in cycle-driven-chemo-start. 💊💉Congrats @vanRheenen_Lab @NKI_nl nature.com/articles/s41586-0…
This is well-deserved! Congrats @deVisserKarin 🥳🥳. She was one of the first scientists recognizing the importance of immune cells in breast tumors. Thanks to key leaders like Karin we now start doing trials specific for BC with high TILs #OPTImal study @NKI_nl @TILsWorkGroup
🎉 Congratulations to @deVisserKarin on receiving the prestigious 2025 Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award! Karin’s groundbreaking work is internationally recognized ➡️ bit.ly/4frxcek
Fantastic PhD program at amazing institution @NKI_nl 👇
📢 Applications for the NKI PhD program open from Jan 1 - Feb 28. Join our international research community in Amsterdam, working in cancer biology, AI research & life sciences with leading scientists and top facilities #PhD #CancerResearch More info: bit.ly/3O4bOjq
MarleenKokLab retweeted
Mensen die naar ons land vluchten voor hun leven, voor de toorn van kwaadaardige regimes die we bestrijden bijvoorbeeld, wil de coalitie vanaf nu elke kans ontnemen nog iets van hun leven te maken…. Er is inderdaad een ernstige crisis gaande in ons land. Een morele crisis.
Stellar line up of speakers and spot on discussions and clinical cases! In the beautiful town of Padua🇮🇹 #AIBCC24 with @MOliveira_MD @vitti10 @prat_aleix @hoperugo and many others!
One of the unmissable meeting of the year, over the past 20 years! #AIBCC24
Now on stage @lab_kok on Immune system and #BreastCancer
@valeguarneri @prat_aleix @vitti10 @GaiaGriguolo @FedeMiglietta
On my way to one of the best conferences on translational cancer research! #MAP24 🚆🚆💚💚
📣 Register now for MAP 2024, 16-18 Oct, London.
Join us for sessions on immune cells in SCLC, anti-tumour immunogenicity, endocrine resistance in breast cancer, FAT1 and the Hippo pathway, and more. #MAP2024
🔗 ow.ly/pmhH50TwSMI
This will be amazing session #SABCS24 with stellar speakers and immune biomarkers inc TILs making their way to the clinic!
State of the Art: The Winding Road of Immune Biomarkers in Early Breast Cancer—
Roberto Salgado, Justin Balko, and Priyanka Sharma will address this topic in this special session at #SABCS24 (December 10-13). Learn more:
bit.ly/4h3tAR0
@BalkoLab @psharmalab
MarleenKokLab retweeted
👀 We're looking for a junior group leader! Join our innovative, curiosity-driven institute in a collaborative, international environment. Full freedom to pursue your research, competitive salary & relocation support.
📅 Apply by Dec 1
Info & application: bit.ly/3BLA3j8
Thanks @ACIR_org for putting our work on neoadjuvant immunotherapy for TNBC in the spotlight @riannerolfes @Manon_deGraaf @LambrechtsDlab @NatureMedicine
In an adaptive, window-of-opportunity phase II neoadjuvant trial in early breast cancer, Nederlof and Isaeva et al. report that 4 weeks of anti-PD-1 or anti-PD-1 + anti-CTLA-4 showed immune activation in 53% and 60% of [...] bit.ly/4dr6tg1 @NKI_nl @lab_kok
MarleenKokLab retweeted
Clinical Cancer Research is seeking a new Editor-in-Chief! Apply by September 30, 2024. Find out more: bit.ly/3zxjJ4U
MarleenKokLab retweeted
Had a fantastic meeting at the #ILCsymposium in beautiful Leuven, Belgium organized by @ChristineDesme2 and her team! Lots to think about, and lot more progress that needs to be made! @oesterreichs @Adrianvlee
Best break-out session ever on TME in lobular BC! Important especially since pts with ILC are often excluded from immunotherapy trials. Thanks for terrific organisation and location @ChristineDesme2 @elbcc #ilcsymposium @oesterreichs
A very impactful #ESMO24. Thanks @RebeccaDSing and great ESMO staff @myESMO @KKronig! Minor note: @NatureMedicine had even more concomitant papers of which 2 from @NKI_nl
‼️28 #ConcomitantPublications highlighting the latest #CancerResearch from #ESMO24.
@Annals_Oncology @NEJM @NatureMedicine @JAMADerm @TheLancet
#ceasefire now! ❤️🩹
A rare, non scientific post on my side…I usually don’t use this platform for it, but I am motivated by others to.
I am half Lebanese, all my father’s family is there, some in the south. My heart breaks for my country and for Gaza, as a Lebanese and a mother. #Ceasefire.
Very excited that we see a 33% pCR rate with only 6 weeks of immunotherapy without chemo in TIL high TNBC. A lay version of our story👇. @NKI_nl @TILsWorkGroup @NatureMedicine
Immunotherapy as a treatment for triple-negative breast cancer appears to be effective even without chemotherapy, according to NKI research. This could prevent overtreatment and side effects associated with chemotherapy ➡️ bit.ly/3BfltjL
👇Wij zoeken een ervaren, enthousiaste, pro-actieve en flexibele Project Manager voor een groot, internationaal onderzoek om biomarker (TILs) naar de kliniek te brengen. werkenbijavl.nl/vacatures/cl…
MarleenKokLab retweeted
#ESMO24
Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in TNBC with high TILs: BELLINI trial
🔍stage I-II, node negative, TILs ≥50%, 30 pts
pCR
Nivo+IPI➡️33%
Nivo+RELA➡️47%
💥Remarkable efficacy of chemotherapy-free immunotherapy for immunogenic TNBC
MarleenKokLab retweeted
Promising results with neoadjuvant nivo/relatlimab (LAG3 mAb) for mostly cT1c TNBC with high TILs: 47% pCR rate, 73% MPR. Immune toxicities remain an issue, with a case of diabetes mellitus. Terrific work from the team of @lab_kok — concomitant @NatureMedicine publication
A simultaneous publication of our BELLINI data @NKI_nl presented today as oral abstract on exploring nivo/ipi in TNBC without chemo. Thanks #ESMO24 and @NatureMedicine!
Out now for #ESMO24! In #BELLINI, pts with early-stage #TNBC received neoadjuvant #Nivolumab w/ or w/o #Ipilimumab, leading to ctDNA clearance & promising clinical response rates, esp. in preselected pts w/ high TIL levels @lab_kok @NKI_nl
nature.com/articles/s41591-0…
